Q-omics provides the consensus-scored FCGR1CP profile across patient tissues and cancer cell-line models. FCGR1CP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FCGR1CP is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, FCGR1CP RNA expression shows 16,228 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where FCGR1CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGR1CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGR1CP survival associations across molecular data types. FCGR1CP RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGR1CP RNA expression–survival associations across cancer types. High FCGR1CP expression shows unfavorable associations in KIRC, UVM, BRCA, KICH and OV, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FCGR1CP RNA expression.
This table summarizes FCGR1CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FCGR1CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGR1CP shows lower tumor expression in LUSC and LUAD and higher tumor expression in KIRC, KIRP, BRCA and HNSC. The KIRC box plot shows higher FCGR1CP RNA expression in tumor versus normal tissue (log2 FC = +1.449, t-test p < 0.001).
This table shows molecular features associated with FCGR1CP in patient tissues and cancer cell lines. In patient samples, FCGR1CP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGR1CP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
